PepTracker App

These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for retatrutide: > highest dose lost 28.3% of body weight in 80 wks > 70 lbs ave > 45% lost 30% or more of their body weight > 65% on the top dose no longer clinically obese Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively. Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.

Today, we took long-overdue action to restore science, accountability, and the rule of law. In September 2023, the Biden FDA pushed a number of peptides into Category 2 — “Bulk Drug Substances that Raise Significant Safety Risks” — driving a dangerous black market that puts Americans at risk. Now, after nominators withdrew 12 peptides, the FDA will remove them from Category 2 and will bring them to PCAC at its next two meetings, beginning in July—where independent experts will rigorously evaluate each substance on its scientific merits using full clinical, pharmacological, and safety evidence. • BPC-157 • Thymosin beta-4 fragment (LKKTETQ) • Epitalon • GHK-Cu (injectable) • MOTS-c • DSIP (Emideltide) • Dihexa Acetate • Ibutamoren Mesylate • Melanotan II • KPV • Semax (heptapeptide) • Cathelicidin LL-37 This action begins to restore regulated access and will immediately begin shifting demand away from the black market. We will follow the science, enforce the law, and deliver the clarity patients, providers, and pharmacies deserve.

GLP-1’s don’t simply cause you to eat less. They reduce inflammation, reduce cancer, improve arthritis pain, reduce alcohol consumption, protect the heart independent of weight loss, stimulate beta cells in the pancreas, keep you from developing type 2, and generally reduce all cause mortality. 😮‍💨 So no, you can’t just “eat less” and get the same benefits.

🚨 BREAKING: FDA APPROVES ELI LILLY GLP-1 PILL $LLY $NVO $HIMS

Expect a massive surge in compounding pharmacies, explicit warning labels on gray market peptides (currently is “not for human use”… ) and steep penalties for any venue besides Lilly selling Retatrutide. And per prediction, NIH budget to be increased 1%. More on that soon…

🚨 BREAKING NEWS: RFK Jr. says ~14 of 19 banned peptides can be legally compounded again by US pharmacies within a few weeks. This will ensure Americans are getting "a good product… from ethical suppliers" vs. black market drug dealers that provide "substandard product" with serious safety risks. The 19 compounds on FDA’s Category 2 compounding safety list include: • BPC-157 • Cathelicidin LL-37 • Emideltide (DSIP) • Epitalon • GHK-Cu (injectable) • GHRP-2 (injectable/nasal) • GHRP-6 • Ipamorelin acetate • Kisspeptin-10 • KPV • Melanotan II • PEG-MGF (pegylated Mechano Growth Factor) • MOTS-C • Semax • Thymosin beta-4 fragment (LKKTETQ) • AOD-9604 • CJC-1295 • Selank acetate (TP-7) • Thymosin-alpha 1 (Ta1) The five least likely to be legalized in a policy shift would be those with the most troubling safety signals or the weakest human data — for example: Melanotan II, Cathelicidin LL-37, GHRP-2, Ipamorelin acetate, and CJC-1295 — because of documented serious adverse events or other red flags in FDA’s risk assessment.